Endocrinology and Metabolism

Original Article

Impact of Health Behaviors on Cardiovascular Risk in Thyroid Cancer Survivors according to Metastasis: A Nationwide Cohort Study: Jeongmin Lee, Jaekyung Lee, Joonseon Park, Kwangsoon Kim, Ja Seong Bae, Kyung-Do Han, Dong-Jun Lim; Received November 3, 2025 Accepted March 12, 2026 Published online June 17, 2026; DOI: https://doi.org/10.3803/EnM.2025.2767 [Epub ahead of print]

394 View
41 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Patients with thyroid cancer receive thyroid-stimulating hormone suppressive therapy and radioactive iodine therapy, which can alter metabolism and affect the association between lifestyle factors and cardiovascular disease (CVD) outcomes. However, it remains unclear how changes in lifestyle relate to CVD risk, particularly according to metastatic status. We investigated the impact of baseline and changing lifestyle behaviors on CVD risk among thyroid cancer patients by metastasis status.
Methods
This study was a nationwide cohort study using data from the Korean National Health Insurance Service claims database with the Cancer Clinical Library Database from the Korea Clinical Data Utilization Network for Research Excellence project. Over a mean follow-up of 5.7 years, 99,742 thyroid cancer patients were analyzed.
Results
Current smoking increased CVD risk in both no metastasis (NM) group (hazard ratio [HR], 1.77; 95% confidence interval [CI], 1.33 to 2.35) and the local metastasis (LM) group (HR, 1.30; 95% CI, 1.00 to 1.68), but not in those with distant metastasis. Regular activity reduced the risk in the NM group (HR, 0.84; 95% CI, 0.79 to 0.96). Alcohol consumption was not significantly associated with the CVD risk. Sustained smoking showed an increased CVD risk in both NM (HR, 1.95; 95% CI, 1.31 to 2.90) and LM (HR, 1.88; 95% CI, 1.28 to 2.77). Sustained regular physical activity was associated with a lower risk of CVD only in NM (HR, 0.68; 95% CI, 0.53 to 0.87).
Conclusion
Sustained smoking increased CVD risk, while regular physical activity was associated with a lower risk of CVD, particularly in those without distant metastasis.

Special Article

Hypothalamus and pituitary gland
Consensus on the Diagnosis of Cushing’s Disease: A Collaborative Statement from the Korean Endocrine Society and Japan Endocrine Society: Jeongmin Lee, Hidenori Fukuoka, Seung Shin Park, A Ram Hong, Jung Hee Kim, Sang Ouk Chin, Han-Sang Baek, Dong-Jun Lim, Kazunori Kageyama, Mitsuru Nishiyama, Shigeyuki Tahara, Kenichi Oyama, Akira Sugawara, Miho Yamashita, Naoko Inoshita, Hiroshi Arima, Byung-Joon Kim, Yoon-Sok Chung, Soon Jib Yoo, Michio Otsuki, Mi-kyung Kim, The Committee of Clinical Practice Guideline of Korean Endocrine Society, Korean Neuroendocrine Study Group of Korean Endocrine Society; Endocrinol Metab. 2026;41(1):1-13. Published online January 1, 2026; DOI: https://doi.org/10.3803/EnM.2025.2707

5,622 View
474 Download

Abstract PDF PubReader ePub: Cushing’s disease (CD) is a rare but serious endocrine disorder caused by excessive cortisol secretion due to adrenocorticotropic hormone–secreting pituitary tumors. Despite recent developments in diagnostic criteria and treatment options, CD remains associated with substantial comorbidities and mortality. Early and accurate diagnosis is thus essential. Both the Korean Endocrine Society (KES) and Japan Endocrine Society (JES) guidelines are intended to standardize diagnostic approaches to CD, and they share common principles; however, notable differences exist, particularly in biochemical testing thresholds and imaging recommendations. This consensus statement integrates clinical evidence and expert practice from both the KES and JES to establish harmonized recommendations for biochemical evaluation, imaging, and differential testing. This unified framework is intended to enhance diagnostic precision and improve clinical outcomes across East Asian populations.

Original Article

Mineral, bone & muscle Big Data Articles (National Health Insurance Service Database)
Low Serum 25-Hydroxyvitamin D as a Risk Factor for Frailty in Community-Dwelling Older Men: A Korean Nationwide Study: Jeongmin Lee, Min-gu Kang, Jeonghoon Ha, Yunju Jo, Dongryeol Ryu, Hee-Won Jung, Ki-Hyun Baek, Beom-Jun Kim; Endocrinol Metab. 2025;40(6):961-973. Published online November 7, 2025; DOI: https://doi.org/10.3803/EnM.2025.2462

2,265 View
126 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Despite the critical role of vitamin D in various biological processes, its impact on frailty—a condition closely linked to biological age—remains inconclusive. This study aimed to explore the association between serum 25-hydroxyvitamin D (25[OH] D) levels and frailty status in older Korean adults, utilizing a comprehensive frailty index (FI) and a nationally representative dataset.
Methods
This cross-sectional study included 6,589 participants aged ≥65 years from the Korea National Health and Nutrition Examination Survey (2008–2012). Frailty was assessed using a deficit accumulation FI based on 38 physical, cognitive, psychological, and social items.
Results
After adjusting for potential confounders, frail men showed 6.8% lower serum 25(OH)D concentrations compared to nonfrail controls (P=0.007). Men in the lowest serum 25(OH)D quartile (≤39.3 nmol/L) exhibited a 5.3% higher FI (P=0.047) and 1.71-fold increased odds of frailty (P=0.005), compared to those in the highest quartile (>63.3 nmol/L). Similarly, men with vitamin D deficiency (<30 nmol/L) exhibited a 9.6% higher FI compared to those with sufficient vitamin D levels (≥50 nmol/L; P=0.004). However, no significant association between serum 25(OH)D concentration and frailty was observed in women across any analysis.
Conclusion
These findings suggest that low serum 25(OH)D concentrations are a potential risk factor for frailty, particularly in men. Further research is warranted to determine whether vitamin D supplementation in such high-risk older adults could help mitigate frailty.

Citations

Citations to this article as recorded by

Oxidative stress in frailty among older adults: are malondialdehyde and superoxide dismutase the key biomarkers?
Yuyang Zhang, Jiali Zheng, Xiaoxiao Zhang, Yanwen Zhang, Kexin Zhang, Yujiao Hao, Yang Li, Tingting Ma, Xinyu Bai, Yulu Wang, Yaogang Wang, Qi Lu, Yue Zhao
Biogerontology.2026;[Epub] CrossRef

Review Articles

Thyroid
The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline: Shinje Moon, Young Shin Song, Kyong Yeun Jung, Eun Kyung Lee, Jeongmin Lee, Dong-Jun Lim, Chan Kwon Jung, Young Joo Park, on Behalf of the Korean Thyroid Association Clinical Guideline Committee; Endocrinol Metab. 2025;40(3):357-384. Published online June 24, 2025; DOI: https://doi.org/10.3803/EnM.2025.2465

9,991 View
267 Download
8 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

In 2024, the Korean Thyroid Association (KTA) introduced a revised Risk Stratification System (K-RSS) for differentiated thyroid cancer, building upon the modified RSS (M-RSS) proposed by the American Thyroid Association in 2015. The K-RSS emphasizes the cumulative impact of coexisting clinical and pathological features, acknowledging that multiple intermediate-risk factors collectively indicate a higher recurrence risk. Histologic classification follows the 2022 World Health Organization classification, consolidating encapsulated follicular-patterned thyroid carcinomas, including invasive encapsulated follicular variant papillary thyroid carcinoma, follicular thyroid carcinoma, and oncocytic carcinoma of the thyroid gland, and stratifying them by the extent of capsular and vascular invasion. High-grade thyroid carcinoma is newly included. Updated criteria for tumor size and extrathyroidal extension (ETE) represent another significant change. BRAF^V600E-mutated papillary thyroid carcinomas measuring 1 to 2 cm are now considered lower risk than previously classified in the M-RSS, while encapsulated follicular-patterned tumors larger than 4 cm are considered higher risk. Both minimal ETE and gross ETE confined to the strap muscles have been downgraded to low and intermediate risk, respectively. These changes are accompanied by updates regarding molecular profiling and surgical margin status. Collectively, these updates aim to minimize overtreatment in low-risk patients, while ensuring intensified management for those at higher risk.

Citations

Citations to this article as recorded by

Development and validation of a machine learning model for predicting high-risk distant metastatic recurrence in differentiated thyroid cancer
Fei Yang, Jie Zhang, Tengfei Liu, Zhijun Zhao
Frontiers in Medicine.2026;[Epub] CrossRef
Impact of Tumor Bilaterality and Multifocality in Predicting Recurrence of Papillary Thyroid Carcinoma: A Retrospective Cohort Study
Eunji Kim, Jun Hyun Park, Ji-Young Park, Jin Hyang Jung, Sang-Woo Lee
Endocrinology and Metabolism.2026; 41(2): 288. CrossRef
Positive prognostic implications of SPHK1 expression in patients with papillary thyroid carcinoma undergoing radioactive iodine therapy
Kyung Won Park, Ja Seong Bae, Dong-Jun Lim, Chan Kwon Jung
Scientific Reports.2026;[Epub] CrossRef
Overdiagnosis and Overtreatment of Thyroid Cancer and Precision Mitigation Strategies—An Integrated Analysis Based on Evidence-Based Medicine and Risk Stratification Models
云菲李
Advances in Clinical Medicine.2026; 16(04): 4980. CrossRef
Clinicopathological profile of high-grade differentiated thyroid carcinoma in an Indonesian tertiary hospital
Novita, Agnes Stephanie Harahap, Maria Francisca Ham, Alfianto Widiono, Chan Kwon Jung
Journal of Pathology and Translational Medicine.2026; 60(3): 338. CrossRef
ATA 2015-2025 risk stratification transition: prognostic significance of N1b disease in papillary thyroid carcinoma with limited nodal burden
Ziqiang Wang, Yangyang Xie, Tingting Wang, Danwei Du, Xue Song
The Oncologist.2026;[Epub] CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2026
Eun Kyung Lee, Seung Heon Kang, Bon Seok Koo, Mijin Kim, Min Joo Kim, Bo Hyun Kim, Ji Won Kim, Dong Gyu Na, Sohyun Park, Ji-In Bang, Kyorim Back, Youngduk Seo, Young-Ik Son, Young Shin Song, Dong Yeob Shin, Jong-Hyuk Ahn, Hwa Young Ahn, So Won Oh, Ho-Ryun
International Journal of Thyroidology.2026; 19(1): 1. CrossRef
Evolution of Follow-up Strategies in Differentiated Thyroid Cancer: a Comparative Review of the 2015 ATA, 2024 KTA, and 2025 ATA Guidelines
Mijin Kim, Bo Hyun Kim
International Journal of Thyroidology.2026; 19(1): 41. CrossRef
From Risk Categories to Risk-Adapted Care: Comparing the 2025 American Thyroid Association and 2024 Korean Thyroid Association Risk Stratification Systems in Differentiated Thyroid Cancer
Won Gu Kim, Mijin Kim
Endocrinology and Metabolism.2026; 41(3): 383. CrossRef
Who Really Needs RAI Ablation Therapy for Low-to-Intermediate Risk Differentiated Thyroid Cancer? Insights from the IoN Trial
Young Joo Park
Clinical Thyroidology®.2025; 37(9): 323. CrossRef
From Classification to Personalization: Advances in Thyroid Cancer Risk Stratification Systems
Mijin Kim, Bo Hyun Kim
Endocrinology and Metabolism.2025; 40(5): 689. CrossRef
Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study
Mijin Kim, Eun Kyung Lee, Kyeong Jin Kim, Soo Myoung Shin, Jinsun Jang, Je Yoon Shin, Meihua Jin, Ja Seong Bae, Kwangsoon Kim, Won Gu Kim, Min Ji Jeon, Seung Heon Kang, Hee Kyung Kim, Jee Hee Yoon, Yea Eun Kang, Hwa Young Ahn, Young Joo Park, Bo Hyun Kim
Thyroid®.2025;[Epub] CrossRef
Diagnostic Challenges, Prognostic Assessment, and Treatment Strategies in High-Grade Differentiated Thyroid Carcinoma
Chan Kwon Jung, Agnes Stephanie Harahap
Endocrinology and Metabolism.2025; 40(6): 830. CrossRef

Thyroid
2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma: Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shinje Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyong Yeun Jung, Chan Kwon Jung, Yoon Young Cho, Dong-Jun Lim, Sun Wook Kim, Young Joo Park, Dong Gyu Na, Jee Soo Kim; Endocrinol Metab. 2025;40(3):307-341. Published online June 24, 2025; DOI: https://doi.org/10.3803/EnM.2025.2461

16,708 View
602 Download
7 Web of Science
9 Crossref

Abstract PDF PubReader ePub

The increasing detection of papillary thyroid microcarcinoma (PTMC) has raised concerns regarding overtreatment. For low-risk PTMC, either immediate surgery or active surveillance (AS) can be considered. To facilitate the implementation of AS, the Korean Thyroid Association convened a multidisciplinary panel and developed the first Korean guideline. AS is recommended for adults with pathologically confirmed Bethesda V–VI PTMC who have no clinical evidence of lymph node or distant metastasis, gross extrathyroidal extension, invasion of the trachea or recurrent laryngeal nerve, or aggressive histology. A baseline assessment requires high-resolution neck ultrasound performed by experienced operators to exclude extrathyroidal extension, tracheal or recurrent laryngeal nerve invasion, and lymph node metastasis; contrast-enhanced neck computed tomography is optional. Patient characteristics, including age, comorbidities, and the capacity for long-term follow-up, should be thoroughly assessed. Shared decision-making should carefully weigh the benefits and risks of surgery versus AS, considering expected oncologic outcomes, potential complications, quality of life, anxiety, medical costs, and patient preference. Follow-up involves neck ultrasound and thyroid function tests every 6 months for 2 years and annually thereafter. Disease progression, defined as significant tumor growth or newly detected nodal or distant metastasis, warrants surgery. Despite remaining uncertainties, this guideline provides a structured framework to ensure oncologic safety and supports patient-centered AS.

Citations

Citations to this article as recorded by

Feasibility and Safety of Active Surveillance in Subcapsular Thyroid Nodules with High Suspicion for Malignancy
Yan Hu, Wei Zhou, Lu Zhang, Weiwei Zhan
Ultrasound in Medicine & Biology.2026; 52(4): 816. CrossRef
Combined Ultrasound and MRI Assessment in Patients Undergoing Reoperation for Recurrent Papillary Thyroid Carcinoma: Oncological Outcomes and Surgical Safety
Zimei Tang, Jie Liu, Rong Wang, Gang Tian, Anwen Ren, Jiexiao Li, Yiran Wang, Wen Yang, Peng Sun, Tao Huang, Ximeng Zhang, Jie Ming
Current Oncology.2026; 33(2): 98. CrossRef
Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects
Yuanyuan Li, Peijie Wang, Jiaxin Cao, Haiyan Liu
The Oncologist.2026;[Epub] CrossRef
Controlled minimally invasive surgical interventions for the treatment of patients with thyroid carcinoma
David D. Dolidze, Zurab A. Bagatelia, Suren G. Laboyan, Arshak V. Vardanyan, Konstantin S. Titov, Ivan N. Lebedinsky, Georgi Genadi Melkonyan, Dmitriy V. Matveev, Nodar N. Gogitidze, Andrei Y. Lukin, Armen R. Oganyan, David G. Gogolashvili, Anastasia V. B
Journal of Experimental and Clinical Surgery.2026; 19(1): 45. CrossRef
Overdiagnosis and Overtreatment of Thyroid Cancer and Precision Mitigation Strategies—An Integrated Analysis Based on Evidence-Based Medicine and Risk Stratification Models
云菲李
Advances in Clinical Medicine.2026; 16(04): 4980. CrossRef
Active surveillance for low-risk papillary thyroid carcinoma: Integrating guidelines, emerging evidence, and directions
Zijing Wu, Kaiang Zhang, Huixian Zhou, Leyi Wan, Jingyuan Zhong, Chunhua Li, Lianggeng Gong, Yun Peng
iScience.2026; 29(6): 115832. CrossRef
Prognostic Factors and Recurrence in Papillary Thyroid Microcarcinoma
Aydan Farzaliyeva, Feride Pınar Altay, Ozlem Turhan Iyidir, Neslihan Bascil Tutuncu
Medicina.2026; 62(5): 981. CrossRef
Optimal cutoff value of fine-needle aspiration thyroglobulin of metastatic lymph node in thyroid cancer patients
Yang Yang, Xianfeng Jiang
European Journal of Surgical Oncology.2025; 51(11): 110428. CrossRef
Low-risk thyroid cancer: surgery or active surveillance—an application of shared decision-making: a narrative review
Min Joo Kim, Eun Kyung Lee, Sun Wook Cho, Yoo Hyung Kim, Kyu Eun Lee, Su-jin Kim, Woochul Kim, Eun-Jae Chung, Jungirl Seok, Yul Hwangbo, Young Ki Lee, Jinsun Jang, Junsun Ryu, Yuh-Seog Jung, Chang Hwan Ryu, Jae Hoon Moon, June Young Choi, Hyeong Won Yu, K
Journal of the Korean Medical Association.2025; 68(9): 573. CrossRef

Original Articles

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
The Triglyceride-Glucose Index and Risk of End-Stage Renal Disease across Different Durations of Type 2 Diabetes Mellitus: A Longitudinal Cohort Study: Mi-sook Kim, Kyu-Na Lee, Jeongmin Lee, Jeongeun Kwak, Seung-Hwan Lee, Hyuk-Sang Kwon, Jing Hughes, Kyung-Do Han, Eun Young Lee; Endocrinol Metab. 2025;40(5):718-726. Published online May 19, 2025; DOI: https://doi.org/10.3803/EnM.2024.2271

7,170 View
112 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the association between the triglyceride-glucose (TyG) index, a marker of insulin resistance, and the risk of end-stage renal disease (ESRD) in individuals with type 2 diabetes mellitus (T2DM), focusing on variations by diabetes duration.
Methods
We analyzed 1,219,148 Korean adults with T2DM from National Health Insurance Service data who underwent biennial health evaluations (2015 to 2016). ESRD was defined using specific procedural codes (V codes), and Cox proportional hazard models were employed to estimate hazard ratios (HRs) for ESRD across TyG index quartiles and diabetes duration categories, adjusting for various confounders.
Results
Over 6,967,381 person-years of follow-up, 7,548 participants developed ESRD. Higher TyG index quartiles were independently associated with increased risk of ESRD, which was more pronounced with longer diabetes duration. The adjusted HR for ESRD in the highest TyG quartile (Q4) compared to the lowest quartile (Q1) was 1.235 (95% confidence interval [CI], 0.995 to 1.533) in new-onset diabetes, and 1.592 (95% CI, 1.465 to 1.730) in those with diabetes for ≥10 years. Compared to the lowest TyG quartile in new-onset diabetes, the adjusted HR for ESRD in the highest quartile with diabetes duration ≥10 years increased to 10.239 (95% CI, 8.440 to 12.422). Subgroup analysis revealed that a higher TyG index consistently increased the risk of ESRD, with stronger associations observed in younger individuals and those without comorbidities.
Conclusion
The TyG index is a significant predictor of ESRD in T2DM, particularly in those with prolonged diabetes duration. Targeting insulin resistance early may mitigate the risk of ESRD in this population.

Citations

Citations to this article as recorded by

Association between TYG-BMI index and asthma in adults over 45 years of age: analysis of Global Burden of Disease 2021, China Health and Retirement Longitudinal Study, and National Health and Nutrition Examination Survey data
Zhuolin Qin, Longqian Li, Cheng Wang
Journal of Asthma.2026; 63(2): 214. CrossRef
The Association Between the Triglyceride–Glucose Index and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study
Munther S. Momani, Raneem Dalaeen, Dia Sarhan, Zaid Sarhan, Suhib Awamleh, Yazan M. Momani, Omar Abu Farsakh
Life.2026; 16(2): 345. CrossRef
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetologia.2026; 69(7): 1858. CrossRef

Diabetes, obesity and metabolism Big Data Articles (National Health Insurance Service Database)
Association between the Triglyceride-Glucose Index and Cardiovascular Risk and Mortality across Different Diabetes Durations: A Nationwide Cohort Study: Jeongeun Kwak, Kyung-Do Han, Eun Young Lee, Seung-Hwan Lee, Dong-Jun Lim, Hyuk-Sang Kwon, Jeongmin Lee; Endocrinol Metab. 2025;40(4):548-560. Published online March 5, 2025; DOI: https://doi.org/10.3803/EnM.2024.2205

7,840 View
260 Download
9 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aimed to assess the association between triglyceride-glucose (TyG) index and cardiovascular disease (CVD) risk and mortality in a large cohort of diabetes patients.
Methods
A retrospective cohort study of 1,090,485 participants from the Korean National Health Insurance Service database was conducted. Participants were stratified into TyG quartiles.
Results
Higher TyG index quartiles were significantly associated with an increased CVD risk and mortality risk. In fully adjusted models, participants in the highest TyG quartile (Q4) had an 18% higher risk of CVD (hazard ratio [HR], 1.18; 95% confidence interval [CI], 1.13 to 1.23) and a 16% higher risk of mortality (HR, 1.16; 95% CI, 1.11 to 1.23) compared to those in the lowest quartile (Q1). The association was particularly pronounced in patients with fasting glucose ≥126 mg/dL (CVD [HR, 1.33; 95% CI, 1.29 to 1.37], mortality [HR, 1.23; 95% CI, 1.20 to 1.26]; P for interaction <0.001). Patients with a diabetes duration of ≥10 years showed the strongest association between the TyG index and CVD risk (HR, 1.44; 95% CI, 1.38 to 1.50), while the mortality risk was particularly elevated in those with a diabetes duration of less than 5 years (HR, 1.23; 95% CI, 1.18 to 1.30). Subgroup analyses revealed stronger associations between TyG index and CVD risk in younger participants, non-obese individuals, and non-smokers.
Conclusion
The TyG index is a significant predictor of CVD and mortality in diabetic patients, particularly in those with poor glycemic control or longer disease duration.

Citations

Citations to this article as recorded by

Preoperative triglyceride–glucose index as a metabolic predictor of surgical site infection after posterior lumbar fusion
Yu Hua, Shaoxing Li, Yuan Jiang, Jinwang Liu
Journal of Orthopaedic Surgery.2026;[Epub] CrossRef
Combined effect of triglyceride-glucose index and glucose disposal rate on cardio-cerebrovascular disease
Hongfei Yang, Chao Sun, Ya Li, You Zhou, Rui Wang, Yingxue Li, Marwan Salih Al-Nimer
PLOS One.2026; 21(2): e0342154. CrossRef
The association between insulin resistance indices and the occurrence of major adverse cardiovascular events in patients with premature myocardial infarction: a prospective cohort study
Yu Zhou, Yuhang Wang, Jingxi Chen, Lai Jiang, Ran Chu, Weiwei Tian, Jiaxin Wang, Yin Liu, Jing Gao
Frontiers in Nutrition.2026;[Epub] CrossRef
Current evidence on lipid ratios for cardiovascular risk assessment in diabetes: A review
E. Carretero-Anibarro, D. Orozco-Beltran
Primary Care Diabetes.2026; 20(3): 292. CrossRef
Continuous glucose monitoring and risks of acute and chronic diabetes-related complications and mortality in adults with type 1 diabetes: a nationwide cohort study
Ji Yoon Kim, Seohyun Kim, Jae Hyeon Kim
Diabetologia.2026; 69(7): 1858. CrossRef
Analysis of the prevalence of dyslipidemia in early-onset schizophrenia patients and its correlation with clinical characteristics
Kehuang Li, Zhiwei Liu, Liang Sun, Jingjing Zhang, Xinglong Yin, Zhaokun Zhang, Changjie Cao
Frontiers in Psychiatry.2026;[Epub] CrossRef
Exploring the relationship between triglyceride-glucose index and peripheral neuropathy in Nigerian patients with type 2 diabetes: a comparison with other metabolic markers
Blessing Kenechi Myke-Mbata, Bruno Basil, Izuchukwu Nnachi Mba, Terna Gav Ambrose
International Journal of Research in Medical Sciences.2026; 14(5): 1812. CrossRef
The Triglyceride-Glucose Index: A Practical Tool for Enhanced Cardiovascular Risk Stratification in Type 2 Diabetes
Jang Won Son
Endocrinology and Metabolism.2025; 40(4): 545. CrossRef
The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses
Jiajun Liu, Jinhua Kang, Pengpeng Liang, Zhangxiao Song, Guiyun Li, Xueshan Jin, Hongyan Wu
Cardiovascular Diabetology.2025;[Epub] CrossRef
Standardized Triglyceride-Glucose and Plasma Atherogenic Indices as Predictors of Diabetic Nephropathy and Coronary Artery Disease in Patients with Type 1 Diabetes Mellitus
Nazif Yalçın, Nizameddin Koca
European Journal of Therapeutics.2025; 32(1): 1. CrossRef

Diabetes, obesity and metabolism
Prevalence of Mortality and Vascular Complications in Older Patients with Diabetes in Korea: Kwang Joon Kim, Jeongmin Lee, Yang Sun Park, Yong-ho Lee, Kyeong Hye Park, Hee-Won Jung, Chang Oh Kim, Man Young Park, Hun-Sung Kim, Bong-Soo Cha; Endocrinol Metab. 2025;40(3):448-458. Published online February 18, 2025; DOI: https://doi.org/10.3803/EnM.2024.2173

5,360 View
117 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the prevalence of diabetes mellitus (DM) and impaired fasting glucose, as well as their management and comorbidities among older Korean adults.
Methods
Data from 269,447 individuals aged 65 years and older from the Korean National Health Insurance Service between 2000 and 2019 were analyzed to evaluate trends in DM prevalence, healthcare utilization, mortality, and complications.
Results
Among 269,447 individuals, 18.6% (n=50,159/269,447) were diagnosed with DM and 27.0% (n=72,670/269,447) had impaired fasting glucose. The DM group had the highest body mass index, waist circumference, and prevalence of current smokers (P<0.001) but not the highest hypertension prevalence. From 2010 to 2019, the prevalence of DM and impaired fasting glucose increased from 15.5% to 21.9% and from 26.0% to 30.6%, respectively. Cancer-related mortality in DM was 1.15 times higher than in those with normal glucose tolerance (P<0.001), and cardiovascular disease-related mortality was 1.32 times higher (P<0.001); all mortalities were higher in female participants. Myocardial infarction (hazard ratio [HR], 1.34; P<0.001), stroke (HR, 1.24; P<0.001), and heart failure (HR, 1.13; P<0.001) were significantly higher in those with DM.
Conclusion
This is the first study to investigate the prevalence of DM and related complications in older individuals based on longterm representative data in Korea. These results highlight the necessity for targeted interventions to enhance management and outcomes in this population.

Citations

Citations to this article as recorded by

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)
Sangmo Hong, Won J. Kim, Sungrae Kim, Jung H. Park, Eun S. Kang, Min K. Moon, Jae T. Kim, Ji‐Oh Mok, Ki Y. Lee, Cheol‐Young Park, Chang B. Lee
Diabetes, Obesity and Metabolism.2026; 28(2): 906. CrossRef

Review Article

Mineral, Bone & Muscle
Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use: Jeonghoon Ha, Youn-Ju Lee, Jinyoung Kim, Chaiho Jeong, Yejee Lim, Jeongmin Lee, Ki-Hyun Baek, on Behalf of the Catholic Medical Center Bone Research Group; Endocrinol Metab. 2025;40(1):47-56. Published online January 13, 2025; DOI: https://doi.org/10.3803/EnM.2024.2125

45,474 View
1,202 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader ePub

Osteoporosis management in post-menopausal women focuses on fracture prevention, with denosumab as a key therapeutic option. Despite its proven efficacy in reducing fracture risk and increasing bone mineral density (BMD) over 10 years, its long-term impact remains uncertain. We evaluated the literature on its efficacy and safety beyond the initial decade. Clinical trials and real-world studies confirm denosumab’s sustained efficacy, especially in lumbar spine BMD, with hip BMD stabilizing. Concerns about adverse events (AEs) like hypocalcemia and osteonecrosis of the jaw necessitate vigilant monitoring. Risks of atypical femoral fractures and malignancies also require attention, despite unclear links to treatment duration. Clinical guidelines for denosumab beyond 10 years are limited, emphasizing the need for careful monitoring. In certain scenarios, such as advanced chronic kidney disease, prolonged denosumab may be required to balance AE risks with fracture prevention benefits. Denosumab shows potential for long-term efficacy in augmenting BMD; however, monitoring for AEs is crucial to guide clinical decision-making effectively.

Citations

Citations to this article as recorded by

Enhancing osteoporosis treatment: emerging roles of engineered exosomes in bone regeneration and repair
Hongtao Li, Hongyu Pan, Minshan Feng
Journal of Translational Medicine.2026;[Epub] CrossRef
Denosumab Therapy Beyond 10 Years: Subsequent Treatment and Densitometric Outcomes
Xi Xiong, Chun Ho Wong, Kimberly H. Tsoi, Connie H.N. Loong, Carol H.Y. Fong, Alan C.H. Lee, Chi Ho Lee, Kathryn C.B. Tan, Yu Cho Woo, Manju Chandran, David T.W. Lui
Endocrine Practice.2026; 32(6): 861. CrossRef
Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations
Gulistan Bahat, Tugba Erdogan, Savas Ozturk, Ozlem Soyluk Selcukbiricik, Serdar Ozkok, Dilek Gogas Yavuz, Mehmet Akif Karan, Jean-Yves Reginster
Drugs & Aging.2026; 43(4): 341. CrossRef
Comment on “Bone fragility and atypical femoral fractures in SLE: role of disease activity, infection, and treatment”
Manish Juneja, Harshawardhan Ramteke, Rakhshanda Khan
Journal of Bone and Mineral Metabolism.2026;[Epub] CrossRef
Synergistic Efficacy of Calcitriol Combined with Denosumab versus Calcitriol Alone in Postmenopausal Osteoporosis: A Retrospective Cohort Study
Xueyuan Li, Ming Hu, Yi Shen
International Journal of Women's Health.2026; Volume 18: 1. CrossRef
Diagnosis and treatment of osteoporosis: 2026 recommendations of the Polish Society for Rheumatology
Piotr Leszczyński, Cezary Iwaszkiewicz, Zbigniew Michał Żuber, Brygida Kwiatkowska, Bogdan Piotr Batko, Katarzyna Krystyna Pawlak-Buś
Rheumatology.2026;[Epub] CrossRef
Good flatmates: immature neutrophils protect bone integrity
Matthias Gunzer
Blood.2025; 146(11): 1259. CrossRef
Rheumatoid Arthritis and Osteoporosis as Prototypes of Immunosenescence in Osteoimmunology: Molecular Pathways of Inflammaging and Targeted Therapies
Ernesto Aitella, Gianluca Azzellino, Ciro Romano, Lia Ginaldi, Massimo De Martinis
International Journal of Molecular Sciences.2025; 26(19): 9268. CrossRef
Significant Response to Denosumab Yet with Severe Rebound Hypercalcemia in a 9-Year-Old Boy with Aneurysmal Bone Cyst: A Case Report
Laurence Allain, Sarah Elbaz, Sayanthen Sathyakumar, William Le Gallou, Christina Coleman, Hallie Coltin, Dardye Eugène, Abha Gupta, Sebastiano A. G. Lava, Samuele Renzi
Children.2025; 12(11): 1524. CrossRef
Biosimilar denosumab CT-P41 in the treatment of osteoporosis
Karel Urbánek
Clinical Osteology.2025; 30(2): 96. CrossRef

Original Articles

Thyroid
In Vitro Investigation of HIF-1α as a Therapeutic Target for Thyroid-Associated Ophthalmopathy: Jeongmin Lee, Jinsoo Lee, Hansang Baek, Dong-Jun Lim, Seong-Beom Lee, Jung-Min Lee, Sang-Ah Jang, Moo Il Kang, Suk-Woo Yang, Min-Hee Kim; Endocrinol Metab. 2024;39(5):767-776. Published online October 16, 2024; DOI: https://doi.org/10.3803/EnM.2024.1952

4,736 View
117 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Thyroid-associated ophthalmopathy (TAO) involves tissue expansion and inflammation, potentially causing a hypoxic microenvironment. Hypoxia-inducible factor (HIF)-1α is crucial in fibrosis and adipogenesis, which are observed in TAO progression. We investigated the effects of hypoxia on orbital fibroblasts (OFs) in TAO, focusing on the role of HIF-1α in TAO progression.
Methods
OFs were isolated from TAO and non-TAO patients (as controls). In addition to HIF-1α, adipogenic differentiation markers including peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein (CEBP) were measured by Western blot, and phenotype changes were evaluated by Oil Red O staining under both normoxia and hypoxia. To elucidate the effect of HIF-1α inhibition, protein expression changes after HIF-1α inhibitor treatment were evaluated under normoxia and hypoxia.
Results
TAO OFs exhibited significantly higher HIF-1α expression than non-TAO OFs, and the difference was more distinct under hypoxia than under normoxia. Oil Red O staining showed that adipogenic differentiation of TAO OFs was prominent under hypoxia. Hypoxic conditions increased the expression of adipogenic markers, namely PPARγ and CEBP, as well as HIF-1α in TAO OFs. Interleukin 6 levels also increased in response to hypoxia. The effect of hypoxia on adipogenesis was reduced at the protein level after HIF-1α inhibitor treatment, and this inhibitory effect was sustained even with IGF-1 stimulation in addition to hypoxia.
Conclusion
Hypoxia induces tissue remodeling in TAO by stimulating adipogenesis through HIF-1α activation. These data could provide insights into new treatment strategies and the mechanisms of adipose tissue remodeling in TAO.

Citations

Citations to this article as recorded by

Hypoxia-Inducible Factor 1-α in Autoimmune Diseases—Insights from the Paradigm of Hashimoto’s Thyroiditis: A Narrative Review
Nika Srb, Andrea Milostić-Srb, Lea Sarić, Dubravka Holik, Matej Šapina, Rajko Fureš, Jasminka Talapko, Ivana Škrlec, Darko Katalinić, Borna Kovačić
Medical Sciences.2026; 14(1): 61. CrossRef
Metabolic reprogramming of Th17/Treg imbalance in autoimmune thyroid diseases
Mengli Zhou, Weijie Wu, Yingzhao Liu, Shengjun Wang, Huiyong Peng
Cell Communication and Signaling.2026;[Epub] CrossRef
Integrative transcriptomic profiling and machine learning reveal hypoxia-associated molecular signatures for precision diagnosis in thyroid eye disease
Weijin Qian, Tianyi Zhu, Jin Liu, Yining Wei, Li Yang, Lianfei Fang, Jing Sun, Yinwei Li, Sijie Fang, Huifang Zhou
Human Genomics.2025;[Epub] CrossRef
Unravelling the pathogenic mechanisms in Graves’ orbitopathy
Alan Chun Hong Lee, George J Kahaly
European Thyroid Journal.2025;[Epub] CrossRef

Thyroid
Exploring the Association between Thyroid Function and Frailty: Insights from Representative Korean Data: Youn-Ju Lee, Min-Hee Kim, Dong-Jun Lim, Jung-Min Lee, Sang Ah Chang, Jeongmin Lee; Endocrinol Metab. 2023;38(6):729-738. Published online November 2, 2023; DOI: https://doi.org/10.3803/EnM.2023.1769

7,115 View
258 Download
8 Web of Science
8 Crossref

Abstract PDF PubReader ePub

Background
This study investigates the association between thyroid function and frailty in the old patients using representative data.
Methods
The study was conducted using data from the Korea National Health and Nutrition Examination Survey conducted from 2013 to 2015. The study population included 2,416 participants aged 50 years and older with available thyroid function test data. Frailty assessment was performed using the Fried frailty phenotype. The prevalence of frailty was analyzed across different thyroid diseases and thyroid function parameters.
Results
The significant association between thyroid dysfunction and frailty was observed in overt hyperthyroidism and subclinical hyperthyroidism. After adjusting for various factors, the association between thyroid dysfunction and frailty remained significant. On the other hand, overt hypothyroidism did not show a significant association with frailty in the adjusted analysis. For individuals with overt hyperthyroidism and subclinical hyperthyroidism, higher levels of free thyroxine (FT4) were significantly associated with an increased risk of frailty (aOR >999; 95% CI, >999 to 999). Among individuals with overt hypothyroidism, lower level of FT4 levels and high thyrotropin (TSH) levels showed a significant association with frailty risk (FT4: aOR, <0.01; TSH: aOR, 999). In participants with subclinical hypothyroidism, there were no significant associations between parameters for thyroid and frailty risk.
Conclusion
These findings suggest that thyroid dysfunction, particularly overt hyperthyroidism and subclinical hyperthyroidism, may be associated with an increased risk of frailty in the old patients.

Citations

Citations to this article as recorded by

Association of iodized salt intake with the risk of physical frailty in patients with type 2 diabetes
Jiang Li, Jie Li, Ying Sun, Yanqi Fu, Wenqi Shen, Lingli Cai, Fei Xu, Ling Gao, Ningjian Wang, Bin Wang, Yingli Lu
The Journal of nutrition, health and aging.2025; 29(6): 100543. CrossRef
Development and validation of a predictive nomogram for frailty based on thyroid function in older adults
Xiaotian Shi, Huayu Yang, Shan Wang, Yifan Yang, Yuanyuan Li, Guoze Dou, Qing Ma
European Geriatric Medicine.2025; 16(5): 1861. CrossRef
Associations between thyroid function, thyroid hormone sensitivity indices, and frailty: Insights from a large cross-sectional study
Yusheng Zhang, Daowen Zhang, Chenwen Yuan, Yiming Wang, Hao Zhu, Yu Duan
Experimental Gerontology.2025; 208: 112822. CrossRef
Subclinical hyperthyroidism
Alasdair Cooper, Prakash Abraham
Current Opinion in Endocrinology, Diabetes & Obesity.2025; 32(5): 175. CrossRef
Endocrine Adaptations to Prolonged Fasting: From Physiology, Clinical Uncertainties, Translational Challenges to Healthspan Implications
Rok Herman, Jure Trsan, Luka Lipar, Mojca Jensterle, Andrej Janez
Nutrients.2025; 17(24): 3949. CrossRef
Associations of thyroid feedback quantile-based index with diabetes in euthyroid adults in the United States and China
Heng Wan, Genfeng Yu, Yajun He, Siyang Liu, Xingying Chen, Yuqi Jiang, Hualin Duan, Xu Lin, Lan Liu, Jie Shen
Annals of Medicine.2024;[Epub] CrossRef
Comorbid Hypothyroidism and Low-Alanine Aminotransferase-Associated Sarcopenia Associated with Shortened Survival: A Retrospective Study of 16,827 Patients over a 21-Year Period
Omer Segal, Rabia Khoury, Adva Vaisman, Gad Segal
Journal of Clinical Medicine.2024; 13(19): 5838. CrossRef
A Neglected Point: Frailty in Older Adults with Differentiated Thyroid Cancer
Meric Coskun, Esra Cataltepe, Hacer Dogan Varan, Eda Ceker, Yasemin Bektas, Yasemin Kuscu, Mehmet Muhittin Yalcin, Mujde Akturk, Fusun Balos Toruner, Mehmet Ayhan Karakoc, Alev Eroglu Altinova
Endocrinology and Metabolism.2024; 39(6): 899. CrossRef

Special Article

Adrenal gland
2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism: Jeonghoon Ha, Jung Hwan Park, Kyoung Jin Kim, Jung Hee Kim, Kyong Yeun Jung, Jeongmin Lee, Jong Han Choi, Seung Hun Lee, Namki Hong, Jung Soo Lim, Byung Kwan Park, Jung-Han Kim, Kyeong Cheon Jung, Jooyoung Cho, Mi-kyung Kim, Choon Hee Chung, The Committee of Clinical Practice Guideline of Korean Endocrine Society, The Korean Adrenal Study Group of Korean Endocrine Society; Endocrinol Metab. 2023;38(6):597-618. Published online October 13, 2023; DOI: https://doi.org/10.3803/EnM.2023.1789

30,686 View
1,442 Download
21 Web of Science
22 Crossref

Abstract PDF PubReader ePub

Primary aldosteronism (PA) is a common, yet underdiagnosed cause of secondary hypertension. It is characterized by an overproduction of aldosterone, leading to hypertension and/or hypokalemia. Despite affecting between 5.9% and 34% of patients with hypertension, PA is frequently missed due to a lack of clinical awareness and systematic screening, which can result in significant cardiovascular complications. To address this, medical societies have developed clinical practice guidelines to improve the management of hypertension and PA. The Korean Endocrine Society, drawing on a wealth of research, has formulated new guidelines for PA. A task force has been established to prepare PA guidelines, which encompass epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and follow-up care. The Korean clinical guidelines for PA aim to deliver an evidence-based protocol for PA diagnosis, treatment, and patient monitoring. These guidelines are anticipated to ease the burden of this potentially curable condition.

Citations

Citations to this article as recorded by

High Plasma Renin and Aldosterone Levels Are Associated With a Unique Phenotype in Primary Hypertension
Jung Sun Cho, Ji-Hoon Jung, Woojin Kwon, Woo-Baek Chung, Sang Hyun Ihm
Korean Circulation Journal.2026; 56(1): 49. CrossRef
Risk of Hypertension and Chronic Kidney Disease Following Aldosterone Dysregulation
Raymond R Townsend, Abiy Agiro, Shan Luan, Kaylen Brzozowski, Erick Moyneur, Paule Tetreault-Langlois, Joanna Huang
American Journal of Hypertension.2026; 39(1): 161. CrossRef
Evaluation of the MAGLUMI non-competitive angiotensin I chemiluminescence immunoassay for measuring renin activity in human plasma
Lina Wu, Baohu Zhang, Yun Zhang, Shucai Yang, Chenyan Shi, Wenfeng Wang, Zhonggang Fang, Li Zhang, Xiaosong Qin
Clinical Chemistry and Laboratory Medicine (CCLM).2026; 64(5): 1142. CrossRef
Early-onset hypertension associated with a CACNA1H variant of uncertain significance: a case report and literature review
Xiang Fang, Ruhui Liu, Jing Zeng
BMC Cardiovascular Disorders.2026;[Epub] CrossRef
Endocrine hypertension: the role of imaging in diagnosis and management
Mohammed Azfar Siddiqui, Irfan Amir Kazi, Frank H Miller, Pardeep K Mittal, Esra Demirtas, Khaled M Elsayes, Ayman Nada
British Journal of Radiology.2026; 99(1180): 733. CrossRef
Evaluating simplified confirmation strategies for primary aldosteronism diagnosis
Kangxin Cai, Qin Luo, Menghui Wang, Mulalibieke Heizhati, Huimin Ma, Weiwei Zhang, Gulinuer Duiyimuhan, Ayinigeer Abulimiti, Li Cai, Wen Jiang, Qing Zhu, Junli Hu, Ling Yao, Delian Zhang, Nanfang Li
European Journal of Medical Research.2026;[Epub] CrossRef
Primary Hyperaldosteronism: Epidemiology, Diagnosis, and Clinical Associations
Christos Savvidis, Charalampos Milionis, Argyro Pachi, Athanasios Tselebis, Ioannis Ilias
Epidemiologia.2026; 7(2): 32. CrossRef
The Burden, Outcomes, and Management of Patients with Aldosterone Dysregulation: A Targeted Literature Review
Gianfranco Parati, Gbenga Ogedegbe, Abiy Agiro, Shan Luan, Harrison Davis, Ian Daniel, Jan McKendrick, Joanna Huang, Raymond R. Townsend
Advances in Therapy.2026; 43(5): 1926. CrossRef
Aldosterone fuels the progression of cardiovascular-kidney -metabolic syndrome: focus on primary aldosteronism spectrum
Huannan Wei, Xinyang Long, Mingli Li, Shengzhu Huang, Jianling Li, Zengnan Mo
Endocrine.2026;[Epub] CrossRef
A modifiable driver of dementia: cognitive impairment in primary aldosteronism
Ying-Ying Zheng, Kai-Ge Feng, Xiang Xie
Hypertension Research.2026;[Epub] CrossRef
Differences in target organ damage between captopril challenge test-defined definitive-positive and borderline-range groups among patients with primary aldosteronism
Naoki Fujiwara, Tatsuya Haze, Hiromichi Wakui, Kouichi Tamura, Mika Tsuiki, Kohei Kamemura, Daisuke Taura, Takamasa Ichijo, Yutaka Takahashi, Minemori Watanabe, Hiroki Kobayashi, Toshifumi Nakamura, Shoichiro Izawa, Norio Wada, Tetsuya Yamada, Kenichi Yok
Hypertension Research.2025; 48(2): 540. CrossRef
Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
Chien‐Wei Huang, Tse‐Ying Huang, Ya‐Fei Yang, Li‐Yang Chang, Yu‐Kang Tu, Vin‐Cent Wu, Jui‐Yi Chen
Journal of the American Heart Association.2025;[Epub] CrossRef
Bridging Global and Local Perspectives on Primary Aldosteronism
Ohk-Hyun Ryu
Endocrinology and Metabolism.2025; 40(2): 195. CrossRef
Subclassification of unilateral primary aldosteronism using an optimal cut-off value for positive CYP11B2 (aldosterone synthase) immunohistochemistry and modified histologic criteria in the Korean population
Won Gi Hong, Byung-Chang Kim, Tae-Yon Sung, Seung Hun Lee, Dong Eun Song
Human Pathology.2025; 163: 105876. CrossRef
Correlation of Histopathologic Subtypes of Primary Aldosteronism with Clinical Phenotypes and Postsurgical Outcomes
Chang Ho Ahn, You-Bin Lee, Jae Hyeon Kim, Young Lyun Oh, Jung Hee Kim, Kyeong Cheon Jung
The Journal of Clinical Endocrinology & Metabolism.2024; 109(8): e1582. CrossRef
Temporal trends in clinical features of patients with primary aldosteronism over 20 years
Seung Shin Park, Chang Ho Ahn, Sang Wan Kim, Jung-Min Koh, Seung Hun Lee, Jung Hee Kim
Hypertension Research.2024; 47(8): 2019. CrossRef
Primary aldosteronism: An underdiagnosed clinical entity
Peeyush Jain, Atul Kaushik, Nilashish Dey, Ashwani Mehta, Shaloo Kapoor, Chhavi Agrawal
Journal of Current Cardiology.2024; 2(2): 65. CrossRef
Historical changes in the clinical features of primary aldosteronism
Takamasa Ichijo
Hypertension Research.2024; 47(10): 2926. CrossRef
Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism
Marco Marcelli, Caixia Bi, John W. Funder, Michael J. McPhaul
Hypertension.2024; 81(10): 2072. CrossRef
Screening and treatment of endocrine hypertension focusing on adrenal gland disorders: a narrative review
Seung Min Chung
Journal of Yeungnam Medical Science.2024; 41(4): 269. CrossRef
Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis
Ting-Wei Kao, Jui-Yi Chen, Jung-Hua Liu, Wen-Hsin Tseng, Chih-Chia Hsieh, Vin-Cent Wu, Yen-Hung Lin, Zheng-Wei Chen
Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
Comparative Analysis of Liquid Chromatography-Tandem Mass Spectrometry and Radioimmunoassay in Determining Plasma Aldosterone Concentration and Plasma Renin Activity for Primary Aldosteronism Screening
So Yoon Kwon, Kyeong-Jin Kim, Soo-Youn Lee, Jae Hyeon Kim
Endocrinology and Metabolism.2024; 39(6): 965. CrossRef

Original Articles

Thyroid
Beyond Acute COVID-19: Investigating the Incidence of Subacute Thyroiditis in Long COVID-19 in Korea: Jeongmin Lee, Gi Hyeon Seo, Keeho Song; Endocrinol Metab. 2023;38(4):455-461. Published online August 8, 2023; DOI: https://doi.org/10.3803/EnM.2023.1711

9,887 View
282 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader ePub

Background
The correlation between acute coronavirus disease 2019 (COVID-19) and subacute thyroiditis (SAT) has not been clearly investigated in “long COVID” patients. We aimed to investigate the incidence of SAT during convalescence and after the acute phase of COVID-19, comparing with that of the general population.
Methods
Data from a total of 422,779 COVID-19 patients and a control group of 2,113,895 individuals were analyzed. The index date was defined as the date 3 months after confirmation of COVID-19. The incidence rate (IR) of SAT and hazard ratios (HRs) were calculated per 100,000 persons. Subgroup analysis included analysis of HRs 90–179 and 180 days post-COVID-19 diagnosis; and additional analysis was conducted according to hospitalization status, sex, and age group.
Results
The IR of SAT was 17.28 per 100,000 persons (95% confidence interval [CI], 12.56 to 23.20) in the COVID-19 group and 8.63 (95% CI, 6.37 to 11.45) in the control group. The HR of COVID-19 patients was 1.76 (95% CI, 1.01 to 3.06; P=0.045). The HR of SAT was 1.39 (95% CI, 0.82 to 2.34; P=0.220) up to 6 months after the index date and 2.30 (95% CI, 1.60 to 3.30; P<0.001) beyond 6 months. The HR for SAT among COVID-19 patients was 2.00 (95% CI, 1.41 to 2.83) in hospitalized patients and 1.76 (95% CI, 1.01 to 3.06) in non-hospitalized patients compared to the control group. The IR of SAT was 27.09 (95% CI, 20.04 to 35.82) for females and 6.47 (95% CI, 3.34 to 11.30) for males. In the 19 to 64 age group, the IR of SAT was 18.19 (95% CI, 13.70 to 23.67), while the IR was 9.18 (95% CI, 7.72 to 10.84) in the 65 to 69 age group.
Conclusion
SAT could be a potential long-term complication of COVID-19. Long-term surveillance for thyroid dysfunction is needed especially in hospitalized, female and young-aged subjects.

Citations

Citations to this article as recorded by

Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study
Shiv Mehrotra-Varma, Roham Hadidchi, Sonya S Henry, Hien Quang Nguyen, Jai Mehrotra-Varma, Michael C Coard, Sagar Changela, Jessilin Collins, Tim Q Duong
The Journal of Clinical Endocrinology & Metabolism.2026; 111(6): e1583. CrossRef
Long-Term Thyroid Complications Post-COVID-19: A Systematic Review
Luai Hommos, Harsh Gohil, Mlaak Rob, Jane Manyama, Haneen Ramy, Nesha Naseem, Hana Nishan, Raghad Sabaawi Ibrahim, Shahad Sabaawi Ibrahim, Vivian Chetachi Eziefula Njoku, Ibrahim Al-Mutawa, Aasiya F. Khan, Sean Holroyd, Dalia Zakaria
Microorganisms.2026; 14(3): 543. CrossRef
COVID-19 pandemic and thyroid diseases
Majd Irsheid, Nitzan Burrack, Merav Fraenkel, Eli Hershkovitz, Uri Yoel
Frontiers in Endocrinology.2026;[Epub] CrossRef
Subacute thyroiditis in pregnancy: a narrative review
Mahmoud Ali Kaykhaei, Zahra Heidari
Thyroid Research.2025;[Epub] CrossRef
Thyroid dysfunction in COVID-19
David Tak Wai Lui, Chi Ho Lee, Yu Cho Woo, Ivan Fan Ngai Hung, Karen Siu Ling Lam
Nature Reviews Endocrinology.2024; 20(6): 336. CrossRef
Subacute Thyroiditis in the Time of COVID-19
Hwa Young Ahn
Endocrinology and Metabolism.2024; 39(1): 186. CrossRef
Occult endocrine disorders newly diagnosed in patients with post-COVID-19 symptoms
Yasuhiro Nakano, Naruhiko Sunada, Kazuki Tokumasu, Hiroyuki Honda, Yuki Otsuka, Yasue Sakurada, Yui Matsuda, Toru Hasegawa, Daisuke Omura, Kanako Ochi, Miho Yasuda, Hideharu Hagiya, Keigo Ueda, Fumio Otsuka
Scientific Reports.2024;[Epub] CrossRef
Risk of Incident Thyroid Dysfunction in the Post-Acute Phase of COVID-19: A Population-Based Cohort Study in Hong Kong
David Tak Wai Lui, Xi Xiong, Ching-Lung Cheung, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Franco Wing Tak Cheng, Lanlan Li, Matthew Shing Hin Chung, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos
Endocrine Practice.2024; 30(6): 528. CrossRef
Subacute Thyroiditis Following COVID-19: A Case of Diagnostic Challenge in the Absence of Neck Pain
Kan Sakai, Tadahiro Yonaha, Takashi Shinzato, Takahiro Taira
Cureus.2024;[Epub] CrossRef
Characterization of food in children with anemia from six months to five years
Jennifer Lizcano Ramírez, Jaritza Lissette Delgado Gonzales, Milton Isaac Delgado Contreras, Jenrry Fredy Chávez-Arizala
SCT Proceedings in Interdisciplinary Insights and Innovations.2024; 2: 328. CrossRef

Thyroid
The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease: Jin Yu, Han-Sang Baek, Chaiho Jeong, Kwanhoon Jo, Jeongmin Lee, Jeonghoon Ha, Min Hee Kim, Jungmin Lee, Dong-Jun Lim; Endocrinol Metab. 2023;38(3):338-346. Published online June 9, 2023; DOI: https://doi.org/10.3803/EnM.2023.1664

8,627 View
177 Download
7 Web of Science
7 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To determine whether baseline thyroid-stimulating immunoglobulin (TSI) bioassay or its early response upon treatment with an anti-thyroid drug (ATD) can predict prognosis of Graves’ disease (GD) in real-world practice.
Methods
This retrospective study enrolled GD patients who had previous ATD treatment with TSI bioassay checked at baseline and at follow-up from April 2010 to November 2019 in one referral hospital. The study population were divided into two groups: patients who experienced relapse or continued ATD (relapse/persistence), and patients who experienced no relapse after ATD discontinuation (remission). The slope and area under the curve at 1st year (AUC_1yr) of thyroid-stimulating hormone receptor antibodies including TSI bioassay and thyrotropin-binding inhibitory immunoglobulin (TBII) were calculated as differences between baseline and second values divided by time duration (year).
Results
Among enrolled 156 study subjects, 74 (47.4%) had relapse/persistence. Baseline TSI bioassay values did not show significant differences between the two groups. However, the relapse/persistence group showed less decremental TSI bioassay in response to ATD than the remission group (–84.7 [TSI slope, –198.2 to 8.2] vs. –120.1 [TSI slope, –204.4 to –45.9], P=0.026), whereas the TBII slope was not significantly different between the two groups. The relapse/persistence group showed higher AUC_1yr of TSI bioassay and TBII in the 1st year during ATD treatment than the remission group (AUC_1yr for TSI bioassay, P=0.0125; AUC_1yr for TBII, P=0.001).
Conclusion
Early changes in TSI bioassay can better predict prognosis of GD than TBII. Measurement of TSI bioassay at beginning and follow-up could help predict GD prognosis.

Citations

Citations to this article as recorded by

Predictors of Treatment Outcomes in Pediatric Graves’ Disease
Do Young Shin, Eungu Kang, Hyo-Kyoung Nam, Kee-Hyoung Lee, Young-Jun Rhie
Journal of Korean Medical Science.2026;[Epub] CrossRef
A Predictive Model for Graves’ Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study
Omar El Kawkgi, David Toro-Tobon, Freddy J.K. Toloza, Sebastian Vallejo, Cristian Soto Jacome, Ivan N. Ayala, Bryan A. Vallejo, Camila Wenczenovicz, Olivia Tzeng, Horace J. Spencer, Jeff D. Thostenson, Dingfeng Li, Jacob Kohlenberg, Eddy Lincango, Sneha M
Endocrine Practice.2025; 31(4): 455. CrossRef
Microvascular Ultrasonography Vascularity Index as a Rapid and Simplified Assessment Tool for Differentiating Graves’ Disease from Destructive Thyroiditis and Managing Thyrotoxicosis
Han-Sang Baek, Chaiho Jeong, Jeonghoon Ha, Dong-Jun Lim
Endocrinology and Metabolism.2025; 40(3): 394. CrossRef
High TRAb Titer at Diagnosis Predicts Persistent Positivity and Relapse in Graves’ Disease after Prolonged Antithyroid Therapy
Zimiao Chen, Jinglu Xu, Wenrui Kang, Yang Zhang, Rujun Chen, Xiaohua Gong
Endocrinology and Metabolism.2025; 40(6): 950. CrossRef
Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study
Xinpan Wang, Tiantian Li, Yue Li, Qiuyi Wang, Yun Cai, Zhixiao Wang, Yun Shi, Tao Yang, Xuqin Zheng
Journal of Translational Medicine.2024;[Epub] CrossRef
Long-term Effect of Thyrotropin-binding Inhibitor Immunoglobulin on Atrial Fibrillation in Euthyroid Patients
Jung-Chi Hsu, Kang-Chih Fan, Ting-Chuan Wang, Shu-Lin Chuang, Ying-Ting Chao, Ting-Tse Lin, Kuan-Chih Huang, Lian-Yu Lin, Lung-Chun Lin
Endocrine Practice.2024; 30(6): 537. CrossRef
Dynamic Risk Model for the Medical Treatment of Graves’ Hyperthyroidism according to Treatment Duration
Meihua Jin, Chae A Kim, Min Ji Jeon, Won Bae Kim, Tae Yong Kim, Won Gu Kim
Endocrinology and Metabolism.2024; 39(4): 579. CrossRef

Mineral, Bone & Muscle
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study: Chaiho Jeong, Jeongmin Lee, Jinyoung Kim, Jeonghoon Ha, Kwanhoon Jo, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Tae-Seo Sohn, Ki-Ho Song, Moo Il Kang, Ki-Hyun Baek; Endocrinol Metab. 2023;38(2):260-268. Published online April 27, 2023; DOI: https://doi.org/10.3803/EnM.2023.1663

7,891 View
163 Download
2 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Persistence with denosumab in male patients has not been adequately investigated, although poor denosumab persistence is associated with a significant risk of rebound vertebral fractures.
Methods
We retrospectively evaluated 294 Korean male osteoporosis patients treated with denosumab at three medical centers and examined their persistence with four doses of denosumab injection over 24 months of treatment. Persistence was defined as the extent to which a patient adhered to denosumab treatment in terms of the prescribed interval and dose, with a permissible gap of 8 weeks. For patients who missed their scheduled treatment appointment(s) during the follow-up period (i.e., no-shows), Cox proportional regression analysis was conducted to explore the factors associated with poor adherence. Several factors were considered, such as age, prior anti-osteoporotic drug use, the treatment provider’s medical specialty, the proximity to the medical center, and financial burdens of treatment.
Results
Out of 294 male patients, 77 (26.2%) completed all four sequential rounds of the denosumab treatment. Out of 217 patients who did not complete the denosumab treatment, 138 (63.6%) missed the scheduled treatment(s). Missing treatment was significantly associated with age (odds ratio [OR], 1.03), prior bisphosphonate use (OR, 0.76), and prescription by non-endocrinologists (OR, 2.24). Denosumab was stopped in 44 (20.3%) patients due to medical errors, in 24 (11.1%) patients due to a T-score improvement over –2.5, and in five (2.3%) patients due to expected dental procedures.
Conclusion
Our study showed that only one-fourth of Korean male osteoporosis patients were fully adherent to 24 months of denosumab treatment.

Citations

Citations to this article as recorded by

Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries
Selvam R. Sendhil, Suzanne M. Cadarette, Sulbh Aggarwal, Arman Oganisian, Andrew R. Zullo, Sarah D. Berry, Michael A. Adegboye, Kaleen N. Hayes
Osteoporosis International.2026; 37(1): 81. CrossRef
Denosumab safety in men with osteoporosis: a disproportionality analysis of the FAERS database
Hou-hong Li, Li Wan, Si-jie He, Wen-long Xie
Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef
Denosumab

Reactions Weekly.2023; 1963(1): 206. CrossRef

Thyroid
Quality of Life of Survivors of Thyroid Cancer Is Not Inferior to That in Subjects without Cancer: Long-Term after Over 5 Years: Jeongmin Lee, Youn-Ju Lee, Dong-Jun Lim, Jung-Min Lee, Sang-Ah Chang, Min-Hee Kim; Endocrinol Metab. 2022;37(4):664-673. Published online August 29, 2022; DOI: https://doi.org/10.3803/EnM.2022.1499

9,193 View
315 Download
7 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Patients with thyroid cancer undergo less extensive surgery and additional therapies compared to those with other cancers. We aimed to compare the quality of life (QoL) between patients with thyroid cancer and healthy subjects using representative data from Korea. Differences in QoL of thyroid cancer survivors according to the duration after cancer diagnosis was also evaluated.
Methods
This population-based cohort study included 50,278 subjects who participated in the Korea National Health and Nutrition Examination Survey between 2007 and 2017. QoL was compared between patients with thyroid cancer and healthy subjects using self-reported data from the EuroQoL (EQ)-5 dimension (5D) and EQ-visual analog scale (VAS). Propensity score matching was used to match thyroid cancer survivors to healthy subjects (1:5 matching).
Results
Linear regression with univariate analysis showed that the presence of thyroid cancer was positively correlated with better EQ-5D index scores (β-coefficient=0.010, p=0.046). After adjusting for multiple covariables, statistical significance was maintained. EQ-VAS fails to demonstrate any significant correlation. Among the EQ-5D categories, patients with thyroid cancer showed better self-care than healthy subjects. Thyroid cancer duration did not correlate with the EQ-5D index score. In subgroup analyses, compared to patients with thyroid cancer duration of <5 years, no significant difference was observed in the correlation between the EQ-5D index score and survival duration in those with thyroid cancer duration of 5 to 9 years and ≥10 years.
Conclusion
Using a large-scale nationwide population-based database, our study demonstrated better QoL, especially in terms of self-care, among thyroid cancer survivors than among healthy subjects without cancer.

Citations

Citations to this article as recorded by

Patient preferences in papillary thyroid microcarcinoma management are driven by aversion toward complications rather than treatment pathway
Rebecca Kowalski, Kendyl Carlisle, Aprill N. Park, Salome Ricci, Reuben Don, Carrie Cunningham, Julia F. Slejko, C. Daniel Mullins, Yinin Hu
Surgery.2026; 189: 109694. CrossRef
Quality of Life in Thyroid Cancer Survivors: The Influence of Obesity
Nadjib Kaouache, Abdelhak Lakehal, Nassim Nouri
AACE Endocrinology and Diabetes.2026; 13(2): 139. CrossRef
Prospective Predictors of Poor Emotional Functioning in Patients with Differentiated Thyroid Carcinoma
Gerasimos P. Sykiotis, Athina Mageiropoulou, Akram Al-Ibraheem, Monica Pinto, Ioannis Iakovou, Arild Andre Østhus, Eva Gamper, Eva Hammerlid, Laura Deborah Locati, Ricardo Ribeiro Gama, Giuseppe Fanetti, Naomi Kiyota, Juan Ignacio Arraras, Johanna Inheste
Thyroid®.2026;[Epub] CrossRef
Impact of Health Behaviors on Cardiovascular Risk in Thyroid Cancer Survivors according to Metastasis: A Nationwide Cohort Study
Jeongmin Lee, Jaekyung Lee, Joonseon Park, Kwangsoon Kim, Ja Seong Bae, Kyung-Do Han, Dong-Jun Lim
Endocrinology and Metabolism.2026;[Epub] CrossRef
Thyroid Cancer Survivors Experience Persistent Symptoms and Health-Related Quality-of-Life Deficits 12 Months Following Surgery
Christine J. O’Neill, Christopher W. Rowe, Harriet Morris-Baguley, Melissa A. Carlson, Sarah Leask, Tara Clinton-McHarg, Elizabeth Holliday, Elizabeth A. Fradgley, Christine L. Paul
Thyroid®.2025; 35(9): 1039. CrossRef
Differences in health state valuation for small, low-risk thyroid cancer between general population and cancer survivors: a cross-sectional analysis
Kendyl Carlisle, Rebecca Kowalski, Aprill N. Park, Salome Ricci, Kai Sun, Carrie Cunningham, Julia F. Slejko, C. Daniel Mullins, Yinin Hu
Quality of Life Research.2025; 34(10): 2891. CrossRef
Longitudinal Changes in Quality of Life Before and After Thyroidectomy in Patients With Differentiated Thyroid Cancer
Byung Hun Kim, Soo Rack Ryu, Jin Won Lee, Chang Myeon Song, Yong Bae Ji, Seok Hyun Cho, Seung Hwan Lee, Kyung Tae
The Journal of Clinical Endocrinology & Metabolism.2024; 109(6): 1505. CrossRef
Quality of Life in Differentiated Thyroid Cancer Patients after Total Thyroidectomy and Radioiodine
Jie Liu
Clinical Thyroidology®.2024; 36(5): 180. CrossRef
Quality-of-Life Changes after Thyroidectomy for Differentiated Thyroid Cancer
Simone de Leo
Clinical Thyroidology®.2024; 36(8): 294. CrossRef
Quality of Life Considerations in Patients Treated for Differentiated Thyroid Cancer
Jie Liu
Clinical Thyroidology.2023; 35(4): 160. CrossRef
The psychosocial impact of thyroid cancer
Parker Haymart, Nina Jackson Levin, Megan R. Haymart
Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(5): 252. CrossRef

First
Prev
Page of 1
Next
Last

Search